These findings indicate that STAT3 activity is required for Olaparib-resistant cell growth and survival, and STAT3 targeting can kill PARPi-resistant ovarian tumor cells and/or restore PARPi sensitivity. Here, STAT3 is linked to ovarian neoplasm.